The modified Glasgow prognostic score is a reliable predictor of oncological outcomes in patients with rectal cancer undergoing neoadjuvant chemoradiotherapy

1. Benson, A. B. 3rd. et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw.

15, 370–398 (2017).

2. Bosset, J. F. et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N. Engl. J. Med. 355, 1114–1123 (2006).

3. Gérard, J. P. et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: Results

of FFCD 9203. J. Clin. Oncol. 24, 4620–4625 (2006).

4. Sauer, R. et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351, 1731–1740 (2004).

5. Glynne-Jones, R. & Hughes, R. Critical appraisal of the “wait and see” approach in rectal cancer for clinical complete responders

after chemoradiation. Br. J. Surg. 99, 897–909 (2012).

6. Maas, M. et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J. Clin. Oncol. 29,

4633–4640 (2011).

7. Cunningham, D. et al. Colorectal cancer. Lancet 375, 1030–1047 (2010).

8. Grade, M., Wolff, H. A., Gaedcke, J. & Ghadimi, B. M. The molecular basis of chemoradiosensitivity in rectal cancer: Implications

for personalized therapies. Langenbecks Arch. Surg. 397, 543–555 (2012).

9. Rödel, C., Hofheinz, R. & Liersch, T. Rectal cancer: State of the art in 2012. Curr. Opin. Oncol. 24, 441–447 (2012).

10. Guthrie, G. J. et al. The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit. Rev.

Oncol. Hematol. 88, 218–230 (2013).

11. McMillan, D. C. The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer.

Cancer Treat. Rev. 39, 534–540 (2013).

12. McMillan, D. C., Crozier, J. E., Canna, K., Angerson, W. J. & McArdle, C. S. Evaluation of an inflammation-based prognostic score

(GPS) in patients undergoing resection for colon and rectal cancer. Int. J. Colorectal Dis. 22, 881–886 (2007).

13. Dolan, R. D. & McMillan, D. C. The prevalence of cancer associated systemic inflammation: Implications of prognostic studies

using the Glasgow Prognostic Score. Crit. Rev. Oncol. Hematol. 150, 102962 (2020).

14. Tuomisto, A. E., Mäkinen, M. J. & Väyrynen, J. P. Systemic inflammation in colorectal cancer: Underlying factors, effects, and

prognostic significance. World J. Gastroenterol. 25, 4383–4404 (2019).

15. Weiser, M. R. AJCC 8th edition: Colorectal cancer. Ann. Surg. Oncol. 25, 1454–1455 (2018).

16. Matsuda, T. et al. Outcomes and prognostic factors of selective lateral pelvic lymph node dissection with preoperative chemoradiotherapy for locally advanced rectal cancer. Int. J. Colorectal Dis. 33, 367–374 (2018).

17. Hashiguchi, Y. et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal

cancer. Int. J. Clin. Oncol. 25, 1–42 (2020).

18. Forrest, L. M., McMillan, D. C., McArdle, C. S., Angerson, W. J. & Dunlop, D. J. Evaluation of cumulative prognostic scores based

on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br. J. Cancer 89, 1028–1030 (2003).

19. Fan, H. et al. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 142, 1285–1297

(2016).

20. Ishizuka, M., Nagata, H., Takagi, K. & Kubota, K. Influence of inflammation-based prognostic score on mortality of patients

undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer. Ann. Surg. 250, 268–272 (2009).

21. Lu, X. et al. Prognostic value of the Glasgow prognostic score in colorectal cancer: A meta-analysis of 9,839 patients. Cancer Manag.

Res. 11, 229–249 (2019).

22. Roncolato, F. T. et al. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC)—Analysis

of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecol. Oncol. 148, 36–41 (2018).

23. Sato, R. et al. Preoperative change of modified Glasgow prognostic score after stenting predicts the long-term outcomes of obstructive colorectal cancer. Surg. Today 50, 232–239 (2020).

24. Abe, S. et al. Poor nutrition and sarcopenia are related to systemic inflammatory response in patients with rectal cancer undergoing

preoperative chemoradiotherapy. Int. J. Colorectal Dis. 37, 189–200 (2022).

25. Liu, H. et al. BMI may be a prognostic factor for local advanced rectal cancer patients treated with long-term neoadjuvant chemoradiotherapy. Cancer Manag. Res. 20(12), 10321–10332 (2020).

26. Abdel-Rahman, O. Effect of body mass index on 5-FU-based chemotherapy toxicity and efficacy among patients with metastatic

colorectal cancer; A pooled analysis of 5 randomized trials. Clin. Colorectal Cancer 18(4), e385–e393 (2019).

27. Kalb, M. et al. Influence of body mass index on long-term outcome in patients with rectal cancer—A single centre experience.

Cancers (Basel) 11(5), E609 (2019).

28. Lee, Y. J. et al. Prognostic impact of immunonutritional status changes during preoperative chemoradiation in patients with rectal

cancer. Ann. Coloproctol 32, 208–214 (2016).

29. Park, J. H., McMillan, D. C., Horgan, P. G. & Roxburgh, C. S. The impact of anti-inflammatory agents on the outcome of patients

with colorectal cancer. Cancer Treat. Rev. 40, 68–77 (2014).

30. Guirguis-Blake, J. M., Evans, C. V., Perdue, L. A., Bean, S. I. & Senger, C. A. Aspirin use to prevent cardiovascular disease and

colorectal cancer: Updated evidence report and systematic review for the US Preventive Services Task Force. Jama 327, 1585–1597

(2022).

31. Rothwell, P. M. et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the

time course of risks and benefits in 51 randomised controlled trials. Lancet 379, 1602–1612 (2012).

32. Wang, B. & Huang, Y. Effect of aspirin use on neoadjuvant chemoradiotherapy for rectal cancer: A meta-analysis with trial sequential analysis. J. Cancer Res. Clin. Oncol. 146, 2161–2171 (2020).

Scientific Reports |

(2023) 13:17111 |

https://doi.org/10.1038/s41598-023-44431-w

Vol.:(0123456789)

www.nature.com/scientificreports/

33. Pourlotfi, A. et al. Statin therapy and its association with long-term survival after colon cancer surgery. Surgery 171, 890–896

(2022).

34. Deva, S. & Jameson, M. Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. Cochrane

Database Syst. Rev. Cd007814 (2012).

35. Wong, T. X. et al. Effects of perioperative oral nutrition supplementation in Malaysian patients undergoing elective surgery for

breast and colorectal cancers—A randomised controlled trial. Nutrients 14, 615 (2022).

Author contributions

T.M., T.O., and S.K. involved in the conception and design of study. A.S., R.S., and H.H. involved in data collection. A.S., K.Y. and H.H. participated in the analysis and interpretation of data. A.S. wrote the main manuscript.

T.M., H.G., and N.U. were responsible for providing critical revisions. All authors reviewed the manuscript.

Competing interests The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to T.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and

institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or

format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the

Creative Commons licence, and indicate if changes were made. The images or other third party material in this

article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the

material. If material is not included in the article’s Creative Commons licence and your intended use is not

permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from

the copyright holder. To view a copy of this licence, visit http://​creat​iveco​mmons.​org/​licen​ses/​by/4.​0/.

© The Author(s) 2023

Scientific Reports |

Vol:.(1234567890)

(2023) 13:17111 |

https://doi.org/10.1038/s41598-023-44431-w

...